RSS-Feed abonnieren
PDF herunterladen
DOI: 10.1055/a-1675-3494
Endocannabinoid Modulation Using Monoacylglycerol Lipase Inhibition in Tourette Syndrome: A Phase 1 Randomized, Placebo-Controlled Study
Funding This study was sponsored by Abide Therapeutics, USA. Funding for editorial support was provided by H. Lundbeck A/S, Denmark. Clinical Trials Registry Registration Clinicaltrials.gov: NCT03058562, registered February 2017.
Abstract
Introduction Tourette syndrome (TS) is a complex neurodevelopmental disorder characterized by chronic motor and vocal tics. While consistently effective treatment is lacking, evidence indicates that the modulation of endocannabinoid system is potentially beneficial. Lu AG06466 (previously ABX-1431) is a highly selective inhibitor of monoacylglycerol lipase, the primary enzyme responsible for the degradation of the endocannabinoid ligand 2-arachidonoylglycerol. This exploratory study aimed to determine the effect of Lu AG06466 versus placebo on tics and other symptoms in patients with TS.
Methods In this phase 1b cross-over study, 20 adult patients with TS on standard-of-care medications were randomized to a single fasted dose of Lu AG06466 (40 mg) or placebo in period 1, followed by the other treatment in period 2. The effects on tics, premonitory urges, and psychiatric comorbidities were evaluated using a variety of scaled approaches at different time points before and after treatment.
Results All scales showed an overall trend of tic reduction, with two out of three tic scales (including the Total Tic Score of the Yale Global Tic Severity Score) showing a significant effect of a single dose of Lu AG06466 versus placebo at various timepoints. Treatment with Lu AG06466 resulted in a significant reduction in premonitory urges versus placebo. Single doses of Lu AG06466 were generally well-tolerated, and the most common adverse events were headache, somnolence, and fatigue.
Conclusion In this exploratory trial, a single dose of Lu AG06466 showed statistically significant positive effects on key measures of TS symptoms.
Publikationsverlauf
Eingereicht: 13. Mai 2021
Eingereicht: 11. Oktober 2021
Angenommen: 12. Oktober 2021
Artikel online veröffentlicht:
30. November 2021
© 2021. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
References
- 1 Bloch MH, Leckman JF. Clinical course of Tourette syndrome. J Psychosom Res 2009; 67: 497-501
- 2 Martino D, Ganos C, Pringsheim TM. Tourette syndrome and chronic tic disorders: The clinical spectrum beyond tics. Int Rev Neurobiol 2017; 134: 1461-1490
- 3 Hirschtritt ME, Lee PC, Pauls DL. et al. Lifetime prevalence, age of risk, and genetic relationships of comorbid psychiatric disorders in Tourette syndrome. JAMA Psychiatry 2015; 72: 325-333
- 4 Quezada J, Coffman KA. Current approaches and new developments in the pharmacological management of Tourette syndrome. CNS drugs 2018; 32: 33-45
- 5 Pringsheim T, Holler-Managan Y, Okun MS. et al. Comprehensive systematic review summary: Treatment of tics in people with Tourette syndrome and chronic tic disorders. Neurology 2019; 92: 907-915
- 6 Ganos C. Tics and Tourette’s: update on pathophysiology and tic control. Curr Opin Neurol 2016; 29: 513-518
- 7 Müller-Vahl KR, Kolbe H, Schneider U. et al. Cannabinoids: Possible role in patho-physiology and therapy of Gilles de la Tourette syndrome. Acta Psychiatr Scand 1998; 98: 502-506
- 8 Abi-Jaoude E, Chen L, Cheung P. et al. Preliminary evidence on cannabis effectiveness and tolerability for adults with Tourette syndrome. J Neuropsychiatry Clin Neurosci 2017; 29: 391-400
- 9 Thaler A, Arad S, Schleider LB. et al. Single center experience with medical cannabis in Gilles de la Tourette syndrome. Parkinsonism Relat Disord 2019; 61: 211-213
- 10 Müller-Vahl KR, Schneider U, Koblenz A. et al. Treatment of Tourette’s syndrome with Delta 9-tetrahydrocannabinol (THC): a randomized crossover trial. Pharmacopsychiatry 2002; 35: 57-61
- 11 Müller-Vahl KR, Schneider U, Prevedel H. et al. Delta 9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: a 6-week randomized trial. J Clin Psychiatry 2003; 64: 459-465
- 12 Howlett AC. The cannabinoid receptors. Prostaglandins Other Lipid Mediat 2002; 68-69: 619-631
- 13 Alger BE, Kim J. Supply and demand for endocannabinoids. Trends Neurosci 2011; 34: 304-315
- 14 Blankman JL, Cravatt BF. Chemical probes of endocannabinoid metabolism. Pharmacol Rev 2013; 65: 849-871
- 15 Leckman JF, Riddle MA, Hardin MT. et al. The Yale Global Tic Severity Scale: Initial testing of a clinician-rated scale of tic severity. J Am Acad Child Adolesc Psychiatry 1989; 28: 566-573
- 16 Goetz CG, Pappert EJ, Louis ED. et al. Advantages of a modified scoring method for the Rush Video-Based Tic Rating Scale. Mov Disord 1999; 14: 502-506
- 17 Abramovitch A, Reese H, Woods DW. et al. Psychometric properties of a self-report instrument for the assessment of tic severity in adults with tic disorders. Behav Ther 2015; 46: 786-796
- 18 McGuire JF, McBride N, Piacentini J. et al. The premonitory urge revisited: An individualized premonitory urge for tics scale. J Psychiatr Res 2016; 83: 176-183
- 19 Goodman WK, Price LH, Rasmussen SA. et al. The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry 1989; 46: 1006-1011
- 20 Walls BD, Wallace ER, Brothers SL. et al. Utility of the Conners’ Adult ADHD Rating Scale validity scales in identifying simulated attention-deficit hyperactivity disorder and random responding. Psychol Assess 2017; 29: 1437-1446
- 21 Beck AT, Epstein N, Brown G. et al. An inventory for measuring clinical anxiety: Psychometric properties. J Consult Clin Psychol 1988; 56: 893-897
- 22 Beck A, Steer RA, Gregory K. BDI-II, Beck Depression Inventory: Manual San Antonio, Tex. Psychological Corp 1196
- 23 Guy W. Clinical global impressions. In: ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: Department of Health, Education, and Welfare, Washington, DC; 1976: 218-222
- 24 Clapper JR, Henry CL, Niphakis MJ. et al. Monoacylglycerol lipase inhibition in human and rodent systems supports clinical evaluation of endocannabinoid modulators. J Pharmacol Exp Ther 2018; 367: 494-508
- 25 Evans J, Seri S, Cavanna AE. The effects of Gilles de la Tourette syndrome and other chronic tic disorders on quality of life across the lifespan: a systematic review. Eur Child Adolesc Psychiatry 2016; 25: 939-948
- 26 Martino D, Pringsheim TM, Cavanna AE. et al. Systematic review of severity scales and screening instruments for tics: Critique and recommendations. Mov Disord 2017; 32: 467-473
- 27 Franzkowiak S, Pollok B, Biermann-Ruben K. et al. Motor-cortical interaction in Gilles de la Tourette syndrome. PLoS One 2012; 7: e27850
- 28 Gerasch S, Kanaan AS, Jakubovski E. et al. Aripiprazole improves associated comorbid conditions in addition to tics in adult patients with Gilles de la Tourette syndrome. Front Neurosci 2016; 10: 416
- 29 Kanaan AS, Jakubovski E, Muller-Vahl K. Significant tic reduction in an otherwise treatment-resistant patient with Gilles de la Tourette syndrome following treatment with nabiximols. Brain Sci 2017; 7
- 30 Maling N, Hashemiyoon R, Foote KD. et al. Increased thalamic gamma band activity correlates with symptom relief following deep brain stimulation in humans with Tourette’s syndrome. PLoS One 2012; 7: e44215
- 31 McGuire JF, Piacentini J, Storch EA. et al. A multicenter examination and strategic revisions of the Yale Global Tic Severity Scale. Neurology 2018; 90: e1711-e1719
- 32 Haas M, Jakubovski E, Fremer C. et al. Yale Global Tic Severity Scale (YGTSS): Psychometric quality of the gold standard for tic assessment based on the large-scale EMTICS Study. Front Psychiatry 2021; 12: 626459
- 33 Milosev LM, Psathakis N, Szejko N. et al. Treatment of Gilles de la Tourette syndrome with cannabis-based medicine: Results from a retrospective analysis and online survey. Cannabis Cannabinoid Res 2019; 4: 265-274
- 34 Cavanna AE, Black KJ, Hallett M. et al. Neurobiology of the premonitory urge in Tourette’s syndrome: Pathophysiology and treatment implications. J Neuropsych Clin Neurosci 2017; 29: 95-104
- 35 Muller-Vahl KR, Bindila L, Lutz B. et al. Cerebrospinal fluid endocannabinoid levels in Gilles de la Tourette syndrome. Neuropsychopharmacology 2020; 45: 1323-1329
- 36 Fraser IP, Blankman J, Clapper J. et al. Preclinical characterization and first-in-human administration of a selective monoacylglycerol lipase inhibitor, ABX-1431. Conference Abstract: EUFEMED 2017; Front Pharmacol 2019
- 37 Robson P. Abuse potential and psychoactive effects of delta-9-tetrahydrocannabinol and cannabidiol oromucosal spray (Sativex), a new cannabinoid medicine. Expert Opin Drug Saf 2011; 10: 675-685
- 38 Tabatadze N, Huang G, May RM. et al. Sex differences in molecular signaling at inhibitory synapses in the hippocampus. J Neurosci 2015; 35: 11252-11265
- 39 Craft RM, Marusich JA, Wiley JL. Sex differences in cannabinoid pharmacology: A reflection of differences in the endocannabinoid system?. Life Sci 2013; 92: 476-481
- 40 Struik D, Sanna F, Fattore L. The modulating role of sex and anabolic-androgenic steroid hormones in cannabinoid sensitivity. Front Behav Neurosci 2018; 12: 249
- 41 Müller-Vahl KR, Fremer C, Beals C, Ivkovic J, Loft H, Schindler C. Monoacylglycerol Lipase Inhibition in Tourette Syndrome: A 12-Week, Randomized, Controlled Study. Mov Disord. 2021 Oct; 36(10):2413- 2418. doi:10.1002/mds.28681